Lymphoid Flashcards
BCR-ABL transcripts
190 - ALL
210 - CML
Ph-like mutations (5)
JAK-STAT - CRLF / EPOR
ABL pathway - ABL, FGFR, PDGFR
Mutation that confers TKI resistance in ALL
T315I
High risk disease for ALL (4)
- MRD end of induction
- MLL (4:11) KMT2A
- IFKZ1
- gain of 21
Relapsed refractory ALL Tx (5)
Young <25 - CART
Older - get to CR and then ALLO
- blina
- ponatinib
- Asciminib
- salvage chemo
Implication of EZH2mut FL
Possible response to tazemetostat
Treatment for Ph + ALL
- consider FOA TKI/ pred (if not going to allo)
- or CALGB 10403, HYPERCVAD, Larson
Translocation genes on chromosome
2
8
11
14
18
22
2 - kappa
8 - myc
11 bcl1 (cycling d1)
14 - igH
18 - bcl2
22 - lambda
DLBCL Tx
Stage I / II contiguous - RCHOP x3 +ISRT or RCHOPx4
Stage II+ BULKY - RCHOPx6
IPET timing for DLBCL
After cycle 3
NCCN recs doe 2L R/R DLBCL
<12m - CART
>12m - salvage chemo
MCL fit and unfit regimens
Fit - RDHAP/R-maxiCHOP
- HYPERCVAD
-RB-RC
Unfit - R Benda
Buekitts regimens
- R CODOX M IVAC
- hyper CVAD
- DA EPOCH R
Polymorphic PTLD Tx
- single site - RT / surgery
- multiple sites - R or RCHOP
Treatment for nMZL
I/II - ISRT
IV - Observation, BR, BTKi
Treatment for enMZL
Gastric I/II
- hpylori without t11:18 - quad
- hpylori with t11:18 - quad and ISRT
- no hpylori - ISRT
IV - observation, BR BTKi
Hairy cell IPT and difference with vHCL
11c/19/20/23/25/103
VHCL without 25
Third line tx for HCL
- muxetumomab
- BRAF
Castlemans dx (3)
1 - fever
2 - CRP >20
3 MOF
Castlemans tx
HHV8 negative - siltuximab
HHV8 positive - rituximab
R/R HL Tx
ICE - Auto - BV x1 year
What virus is associated with primary effusion lymphoma (PEL)
HHV8
PTCL Tx
Transplant eligibility
- CHOEP
-BV CHP
ineligible
CHOP
